118 related articles for article (PubMed ID: 14534349)
21. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
Goldman JM; Melo JV
N Engl J Med; 2001 Apr; 344(14):1084-6. PubMed ID: 11287980
[No Abstract] [Full Text] [Related]
22. Chronic myeloid leukemia with a novel four-way t(6;13;9;22)(p21;q32;q34;q11.2) successfully treated with imatinib mesylate.
Kubota Y; Waki M
Cancer Genet Cytogenet; 2010 Sep; 201(2):135-6. PubMed ID: 20682400
[No Abstract] [Full Text] [Related]
23. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
Iacobucci I; Saglio G; Rosti G; Testoni N; Pane F; Amabile M; Poerio A; Soverini S; Bassi S; Cilloni D; Bassan R; Breccia M; Lauria F; Izzo B; Merante S; Frassoni F; Paolini S; Montefusco E; Baccarani M; Martinelli G;
Clin Cancer Res; 2006 May; 12(10):3037-42. PubMed ID: 16707599
[TBL] [Abstract][Full Text] [Related]
24. Trisomy 8 finding treatment of imatinib mesylate in chronic myeloid leukemia cases.
Tunca Y; Güran S
Exp Hematol; 2005 Feb; 33(2):151. PubMed ID: 15676207
[No Abstract] [Full Text] [Related]
25. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.
Kantarjian HM; Talpaz M; Cortes J; O'Brien S; Faderl S; Thomas D; Giles F; Rios MB; Shan J; Arlinghaus R
Clin Cancer Res; 2003 Jan; 9(1):160-6. PubMed ID: 12538464
[TBL] [Abstract][Full Text] [Related]
26. CML patient with rare b 2 a 3 (e 13 a 3) variant of BCR-ABL transcript: complete molecular response to imatinib.
Moravcová J; Rulcová J; Polák J; Zemanová Z; Klamová H; Haskovec C
Leuk Res; 2005 Nov; 29(11):1365-6. PubMed ID: 15876454
[No Abstract] [Full Text] [Related]
27. The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients.
Piccaluga PP; Malagola M; Amabile M; Rondoni M; Paolini S; Pane F; Russo D; Visani G; Baccarani M; Martinelli G
Haematologica; 2004 Oct; 89(10):1269-71. PubMed ID: 15477218
[TBL] [Abstract][Full Text] [Related]
28. Prolonged treatment with imatinib mesylate in patients with advanced chronic myeloid leukemia causes a reduction of bcr/abl mRNA levels independent of cytogenetic response.
Cariani E; Capucci M; Micheletti M; Spalenza F; Zanella I; Albertini A; Rossi G
Ann Hematol; 2003 Jun; 82(6):333-5. PubMed ID: 12734675
[TBL] [Abstract][Full Text] [Related]
29. [Molecular monitoring: an essential component of the treatment for chronic myeloid leukemia].
Lange T; Pelz-Ackermann O; Burkhardt R; Niederwieser D
Dtsch Med Wochenschr; 2006 Oct; 131(43):2390-4. PubMed ID: 17054054
[No Abstract] [Full Text] [Related]
30. Chronic phase of ETV6-ABL1 positive CML responds to imatinib.
Kawamata N; Dashti A; Lu D; Miller B; Koeffler HP; Schreck R; Moore S; Ogawa S
Genes Chromosomes Cancer; 2008 Oct; 47(10):919-21. PubMed ID: 18615681
[No Abstract] [Full Text] [Related]
31. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
[TBL] [Abstract][Full Text] [Related]
32. Successful peripheral blood stem cell mobilization with granulocyte colony-stimulating factor in a patient with chronic myeloid leukemia achieving a complete cytogenetic remission with dasatinib after failing imatinib.
Gabriel I; Chaidos A; Sorouri J; Dannie E; Davis J; Goldman J; Apperley J; Marin D
Leukemia; 2008 Aug; 22(8):1618-9. PubMed ID: 18305564
[No Abstract] [Full Text] [Related]
33. Durability of molecular remission in chronic myeloid leukemia patients treated with imatinib vs allogeneic stem cell transplantation.
Lange T; Bumm T; Mueller M; Otto S; Al-Ali HK; Grommisch L; Musiol S; Franke C; Krahl R; Niederwieser D; Deininger MW
Leukemia; 2005 Jul; 19(7):1262-5. PubMed ID: 15858618
[No Abstract] [Full Text] [Related]
34. Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Commentary re: A. N. Mohamed et al., The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. Clin. Cancer Res., 9: 1333-1337, 2003.
Marcucci G; Perrotti D; Caligiuri MA
Clin Cancer Res; 2003 Apr; 9(4):1248-52. PubMed ID: 12684391
[No Abstract] [Full Text] [Related]
35. Persistence of molecular remission throughout pregnancy in CML after imatinib.
Sorà F; De Matteis S; Bajer J; D'alò F; Leone G; Sica S
Leuk Res; 2009 Jun; 33(6):e6-7. PubMed ID: 18937976
[No Abstract] [Full Text] [Related]
36. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.
Frater JL; Tallman MS; Variakojis D; Druker BJ; Resta D; Riley MB; Hrisinko MA; Peterson LC
Am J Clin Pathol; 2003 Jun; 119(6):833-41. PubMed ID: 12817431
[TBL] [Abstract][Full Text] [Related]
37. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
[TBL] [Abstract][Full Text] [Related]
38. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia.
Hughes T; Branford S
Blood Rev; 2006 Jan; 20(1):29-41. PubMed ID: 16426942
[TBL] [Abstract][Full Text] [Related]
39. CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: two case reports.
Abruzzese E; Cantonetti M; Morino L; Orlandi G; Tendas A; Del Principe MI; Masi M; Amadori S; Orlandi A; Anemona L; Campione E
J Clin Oncol; 2003 Nov; 21(22):4256-8. PubMed ID: 14615464
[No Abstract] [Full Text] [Related]
40. Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients.
Bianchini M; De Brasi C; Gargallo P; Gonzalez M; Bengió R; Larripa I
Eur J Haematol; 2009 Apr; 82(4):292-300. PubMed ID: 19191867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
